A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

CTTQ

Status and phase: Enrolling; Phase 3

Conditions: HER2-positive Breast Cancer

Treatments: Drug: Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection; Drug: TQB2102 for injection

Study type: Interventional

Funder types: Industry

Identifiers

NCT07043725

TQB2102-III-05

Details and patient eligibility

About

This is a randomized, open, positive drug control, multi center phase III study. Through the evaluation of tpCR, bpCR, ORR, EFS, IDFS, OS , AEs and other indicators, it proves the effectiveness and safety of TQB2102 for injection versus TCbHP in the neoadjuvant treatment of HER2 positive breast cancer patients.

Enrollment: 544 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Voluntarily participate in this study, sign the informed consent form, and have good compliance;
• Eastern Cooperative Oncology Group performance status (ECOG PS) score: 0-1; expected survival >6 months;
• Histologically or cytologically confirmed HER2-positive invasive breast cancer;
• Hormone receptor (HR) status confirmed;
• Clinical stage at diagnosis: T2-4 with any N, M0, or any T with N1-3, M0;
• Agree to undergo breast cancer resection if meeting surgical criteria after neoadjuvant therapy;
• Major organ function is adequate, meeting specific criteria;
• Must agree to use contraception during the study and for 6 months after study completion; female patients must have a negative serum pregnancy test within 7 days before enrollment and must not be lactating; male subjects must agree to use contraception during the study and for 6 months after study completion

Exclusion criteria

• Stage IV metastatic breast cancer or other cases judged by the investigator as unsuitable for radical surgical resection after neoadjuvant therapy;

• Bilateral breast cancer or inflammatory breast cancer;

• History of invasive breast cancer or ductal carcinoma in situ;

• Prior anti-tumor therapy for breast cancer, including chemotherapy, endocrine therapy, targeted therapy, radiotherapy, surgery, etc.;

• Comorbidities and medical history:

  • Other malignancies within 5 years or currently;
  • Adverse reactions from prior treatment not recovered to CTCAE v5.0 grade ≤1;
  • Major surgery, significant traumatic injury within 4 weeks before first dose, or anticipated major surgery during the study, or unhealed wounds/fractures;
  • Conditions affecting intravenous injection or blood sampling;
  • Congenital bleeding or coagulation disorders, or bleeding/coagulation disorders within 28 days before study treatment, or use of aspirin >325 mg/day (maximum antiplatelet dose), dipyridamole, ticlopidine, clopidogrel, or cilostazol within 7 days before study treatment;
  • Arterial/deep venous thrombotic events within 6 months before first dose, e.g., cerebrovascular accident, deep vein thrombosis, pulmonary embolism;
  • Poorly controlled blood pressure (systolic ≥150 mmHg or diastolic ≥100 mmHg);
  • Significant cardiovascular disease, including；
  • Uncontrolled ≥CTCAE grade 2 infection within 14 days before study treatment;
  • History of interstitial lung disease/pneumonitis (non-infectious) requiring steroid treatment, current interstitial lung disease/pneumonitis, or suspected interstitial lung disease/pneumonitis on screening imaging that cannot be ruled out;

• Tumor-related symptoms and treatment:

  • Prior excisional biopsy of primary tumor and/or axillary lymph nodes or sentinel lymph node biopsy before study treatment;
  • Surgery, chemotherapy, radiotherapy, or other anti-tumor therapy within 3 weeks before study treatment (washout period calculated from last treatment);
  • Prior taxane or carboplatin therapy for any malignancy;
  • Treatment with National Medical Products Administration-approved traditional Chinese medicine with clear anti-tumor indications within 2 weeks before study treatment.

• Study treatment-related:

  • Severe hypersensitivity to monoclonal antibodies;
  • Uncontrolled active autoimmune disease within 2 weeks before study treatment;
  • Allergy to any study drug or its components/excipients;
  • Live vaccination within 28 days before study treatment, including measles, mumps, rubella, varicella, yellow fever, seasonal flu, Influenza A virus subtype (H1N1) flu, rabies, Bacille Calmette-Guerin vaccine (BCG), and typhoid vaccines.

• Any condition judged by the investigator to jeopardize subject safety or study completion.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

544 participants in 2 patient groups

TQB2102 for injection

Experimental group

Description:

6mg/kg TQB2102 for injection, Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, 8 cycles.

Treatment:

Drug: TQB2102 for injection

Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection

Active Comparator group

Description:

Trastuzumab injection (The first dose is 8mg/kg, followed by 6mg/kg), Pertuzumab Injection (The first dose is 840, followed by 420mg), Docetaxel Injection (75mg/m2 ) combined with Carboplatin Injection (AUC-6, 800 mg max), Intravenous infusion, administered every 3 weeks, 21 days as a treatment cycle, 6 cycles.

Treatment:

Drug: Trastuzumab injection and Pertuzumab Injection and Docetaxel Injection and Carboplatin Injection